Angiopoietin-1 in the treatment of ischemia and sepsis

Shock

Volumn 31, Issue 4, 2009, Pages 335-341

  Novotny, Nathan M ^a   Lahm, Tim ^a   Markel, Troy A ^a   Crisostomo, Paul R ^a   Wang, Meijing ^a   Wang, Yue ^a   Tan, Jiangning ^a   Meidrum, Daniel R ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Angiopoietin 1; Ischemia; Sepsis; Vascular endothelial growth factor; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL; BLOOD VESSEL PERMEABILITY; CELL THERAPY; DRUG BINDING; EMBRYO DEVELOPMENT; HEART FUNCTION; ISCHEMIC HEART DISEASE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; SEPSIS; STEM CELL;

EID: 64849114225     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181862c63     Document Type: Review

References (118)

1. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, et al: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169, 1996.
2. Colen KL, Crisera CA, Rose MI, Connelly PR, Longaker MT, Gittes GK: Vascular development in the mouse embryonic pancreas and lung. J Pediatr Surg 34:781-785, 1999.
3. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C: Protective role of angiopoietin-1 in endotoxic shock. Circulation 111: 97-105, 2005.
4. Gilroy DW, Vallance P: Resolution for sepsis? Circulation 111:2-4, 2005.
5. Giuliano JS Jr, Lahni PM, Harmon K, Wong HR, Doughty LA, Carcillo JA, Zingarelli B, Sukhatme VP, Parikh SM, Wheeler DS: Admission angiopoietin levels in children with septic shock. Shock 28:650-654, 2007.
6. Mitsuma W, Kodama M, Hirono S, Ito M, Ramadan MM, Tanaka K, Hoyano M, Saigawa T, Kashimura T, Fuse K, et al.: Angiopoietin-1, angiopoietin-2 and Tie-2 in the coronary circulation of patients with and without coronary collateral vessels. Circ J 71:343-347, 2007.
7. Jiang S, Haider H, Idris NM. Salim A, Ashraf M: Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 99: 776-784, 2006.
8. Bach F, Uddin FJ, Burke D: Angiopoietins in malignancy. Eur J Surg Oncol 33:7-15, 2007.
9. Shim WS, Teh M, Bapna A, Kim I, Koh GY, Mack PO, Ge R: Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res 279:299-309, 2002.
10. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT: Biology of hepatocellular carcinoma. Ann Surg Oncol 15:962-971, 2008.
11. Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A: Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 139:329-336, 2003.
12. Kanazawa H, Nomura S, Asai K: Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients. Chest 131: 1035-1041, 2007.
13. Gallagher DC, Parikh SM, Balonov K, Miller A, Gautam S, Talmor D, Sukhatme VP: Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 29:656-661, 2008.
14. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM: Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98:2081-2087, 1998.
15. Abdulmalek K, Ashur F, Ezer N, Ye F, Magder S, Hussain SN: Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. Am J Physiol Lung Cell Mol Physiol 281:L582-L590, 2001.
16. Ramsauer M, D'Amore PA: Getting Tie(2)d up in angiogenesis. J Clin Invest 110:1615-1617, 2002.
17. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM: The role of the complement system in ischemia-reperfusion injury. Shock 21: 401-409, 2004.
18. Marzocco S, Di Paola R, Autore G, Mazzon E, Pinto A, Caputi AP, Thiemermann C, Cuzzocrea S: Calpain inhibitor I reduces intestinal ischemia-reperfusion injury in the rat. Shock 21:38-44, 2004.
19. Shames BD, Barton HH, Reznikov IX, Cairns CB, Banerjee A, Harken AH, Meng X: Ischemia alone is sufficient to induce TNF-alpha mRNA and peptide in the myocardium. Shock 17:114-119, 2002.
20. Meldrum DR, Cleveland JC Jr, Mitchell MB, Rowland RT, Banerjee A, Harken AH: Constructive priming of myocardium against ischemiareperfusion injury. Shock 6:238-242, 1996.
21. Abdelrahman M, Sharpies EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C: Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22: 63-69, 2004.
22. Liu P, Xu B, Forman LJ, Carsia R, Hock CE: L-NAME" enhances microcirculatory congestion and cardiomyocyte apoptosis during myocardial ischemia-reperfusion in rats. Shock 17:185-192, 2002.
23. Cryer HG: Therapeutic approaches for clinical ischemia and reperfusion injury. Shock 8:26-32, 1997.
24. Liu X, Wu X, Cai L, Sun S: Calreticulin downregulation is associated with FGF-2-induced angiogenesis through calcineurin pathway in ischemic myocardium. Shock 29:140-148, 2008.
25. Okuda M: A mnltidisciplinary overview of cardiogenic shock. Shock 25: 557-570, 2006.
26. Crisostomo PR, Meldrum DR: Stem cell delivery to the heart: clarifying methodology and mechanism. Crit Care Med 35:2654-2656, 2007.
27. Crisostomo PR, Wang M, Markel TA, Lahm T, Abarbanell AM, Herrmann JL, Meldrum DR: Stem cell mechanisms and paracrine effects: potential in cardiac surgery. Shock 28:375-383, 2007.
28. Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, et al.: Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A 96:1904-1909, 1999.
29. Lemieux C, Maliba R, Favier J, Theoret JF, Merhi Y, Sirois MG: Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 105:1523-1530, 2005.
30. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70-74, 1995.
31. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al.: Angiopoietin- 2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997.
32. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell Al, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD, Stewart DJ: Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49: 659-670, 2001.
33. Mochizuki Y, Nakamura T, Kanetake H, Kanda S: Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci 115:175-183, 2002.
34. Maliba R, Lapointe S, Neagoe PE, Brkovic A, Sirois MG: Angiopoietins-1 and -2 are both capable of mediating endothelial PAF synthesis: intracellular signalling pathways. Cell Signal 18:1947-1957, 2006.
35. Veikkola T, Alitalo K: Dual role of Ang2 in postnatal angiogenesis and lymphangiogenesis. Dev Cell 3:302-304, 2002.
36. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180, 1996.
37. Abdel-Malak NA, Srikant CB, Kristof AS, Magder SA, Di Battista JA, Hussain SN: Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8. Blood 111:4145-4154,2008.
38. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY: Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/ Akt signal transduction pathway. Circ Res 86:24-29, 2000.
39. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY: Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphaudylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 19: 4549-4552, 2000.
40. Bogdanovic E, Nguyen VP, Dumont DJ: Activation of Tie2 by angiopoietin- 1 and angiopoietin-2 results in their release and receptor internalization. J Cell Sci 119:3551-3560, 2006.
41. Brkovic A, Pelletier M, Girard D, Sirois MG: Angiopoietin chemotactic activities on neutrophils are regulated by PI-3K activation. J Leukoc Biol 81: 1093-1101,2007.
42. DeBusk LM, Hallahan DE, Lin PC: Akt is a major angiogenic mediator downstream of the Angl/Tie2 signaling pathway. Exp Cell Res 298:167-177, 2004.
43. Maliba R, Brkovic A, Neagoe PE, Villeneuve LR, Sirois MG: Angiopoietinmediated endothelial P-selectin translocation: cell signaling mechanisms. J Leukoc Biol 83:352-360, 2008.
44. Lahm T, Crisostomo PR, Markel TA, Wang M, Lillemoe KD, Meldrum DR: The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Shock 28:4-14, 2007.
45. Pickkers P, Sprang T, Eijk L, Hoeven H, Smits P, Deuren M: Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 24:508-512,2005.
46. Meng X, Brown JM, Ao L, Shames BD, Banerjee A, Harken AH: Reduction of infarct size in the rat heart by LPS preconditioning is associated with expression of angiogenic growth factors and increased capillary density. Shock 12:25-31, 1999.
47. + cells may attenuate spinal cord injury by stimulating vascular endothelial and neurotrophic factors. Shock 29:49-55, 2008.
48. van Eijk LT, Nooteboom A, Hendriks T, Sprang T, Netea MG, Smits P, van der Hoeven JG, Pickkers P: Plasma obtained during human endotoxemia increases endothelial albumin permeability in vitro. Shock 25:358-362, 2006.
49. Wang Y, Crisostomo PR, Wang M, Weil B, Abarbanell A, Poynter J, Manukyan MC, Meldrum DR: Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells. Shock 30:527-531, 2008.
50. Crisostomo PR, Wang M, Herring CM, Morrell ED, Seshadri P, Meldrum KK, Meldrum DR: Sex dimorphisms in activated mesenchymal stem cell function. Shock 26:571-574, 2006.
51. Uray KS, Laine GA, Xue H, Allen SJ, Cox CS Jr: Edema-induced intestinal dysfunction is mediated by STAT3 activation. Shock 28:239-244, 2007.
52. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell- Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996.
53. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD: Increased vascularization in mice overexpressing angiopoietin-1. Science 282:468-471, 1998.
54. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W: Angiopoietin- 1 induces sprouting angiogenesis in vitro. Curr Biol 8:529-532, 1998.
55. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983.
56. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6:460-463, 2000.
57. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511-2514, 1999.
58. Gavard J, Patel V, Gutkind JS: Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 14: 25-36, 2008.
59. Makinde T, Murphy RF, Agrawal DK: Immunomodulatory role of vascular endothelial growth factor and angiopoietin-1 in airway remodeling. Curr Mol Med 6:831-841, 2006.
60. Findley CM, Cudmore MJ, Ahmed A, Kontos CD: VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 27:2619-2626, 2007.
61. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY: Plasma angiopoietin- 1, angiopoietin-2, and angiopoietin receptor Tie-2 levels in congestive heart failure. J Am Coll Cardiol 43:423-428, 2004.
62. Chung NA, Makin AJ, Lip GY: Measurement of the soluble angiopoietin receptor Tie-2 in patients with coronary artery disease: development and application of an immunoassay. Eur J Clin Invest 33:529-535, 2003.
63. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D: Soluble Tie2 and Fltl extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 7:1992-1997, 2001.
64. Lip PL, Chatterjee S, Caine GJ, Hope-Ross M, Gibson J, Blann AD, Lip GY: Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor Tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 88: 1543-1546, 2004.
65. Aplin AC, Gelati M, Fogel E, Carnevale E, Nicosia RF: Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. Physiol Genomics 27:20-28, 2006.
66. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 274: R577-R595, 1998.
67. Peters KG: Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res 83:342-343, 1998.
68. Yamauchi A, Ito Y, Morikawa M, Kobune M, Huang J, Sasaki K, Takahashi K, Nakamura K, Dehari H, Niitsu Y, et al.: Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. J Gene Med 5:994-1004, 2003.
69. Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, Ko JK, Koh GY: Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 20: 2573-2578, 2000.
70. Shyu KG, Chang H, Isner JM: Synergistic effect of angiopoietin-1 ant vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci 73:563-579, 2003.
71. Chen F, Tan Z, Dong CY, Chen X, Guo SF: Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs. Acta Pharmacol Sin 28:493-502, 2007.
72. Niagara MI, Haider H, Ye L, Koh VS, Lim YT, Poh KK, Ge R, Sim EK: Autologous skeletal myoblasts transduced with a new adenoviral bicistronic vector for treatment of hind limb ischemia. J Vasc Surg 40:774-785, 2004.
73. Liu X, Chen Y, Zhang F, Chen L, Ha T, Gao X, Li C: Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium. Scand Cardiovasc J 41:95-101, 2007.
74. Ye L, Haider H, Jiang S, Tan RS, Ge R, Law PK, Sim EK: Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1. Eur J Heart Fail 9:15-22, 2007.
75. Su H, Takagawa J, Huang Y, Arakawa-Hoyt J, Pons J, Grossman W, Kan YW: Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart. Int J Cardiol. 2008 Feb 21. [Epub ahead of print]
76. van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP: Plasma vascular endothelial growth factor in severe sepsis. Shock 23:35-38, 2005.
77. Chaudry IH, Clemens MG, Baue AE: The role of ATP-magnesium in ischemia and shock. Magnesium 5:211-220, 1986.
78. McDonagh PF, Laks H, Chaudry IH, Baue AE: Improved myocardial recovery from ischemia. Treatment with low-dose adenosine triphosphatemagnesium chloride. Arch Surg 119:1379-1384, 1984.
79. Mizushima Y, Wang P, Jarrar D, Cioffi WG, Bland KI, Chaudry IH: Preinduction of heat shock proteins protects cardiac and hepatic functions following trauma and hemorrhage. Am J Physiol Regul Integr Comp Physiol 278:R352-R359, 2000.
80. Raeburn CD, Zimmerman MA, Arya J, Banerjee A, Harken AH: Stem cells and myocardial repair. J Am Coll Surg 195:686-693, 2002.
81. Pomerantz BJ, Harken AH: Ischemia and the myocardium. Adv Card Surg 12:23-36, 2000.
82. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA: Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-lbeta. Proc Natl Acad Sci U S A 98:2871-2876, 2001.
83. Pomerantz BJ, Joo K, Shames BD, Cleveland JC Jr, Banerjee A, Harken AH: Adenosine preconditioning reduces both pre and postischemic arrhythmias in human myocardium. J Surg Res 90:191-196, 2000.
84. Dai Y, Ashraf M, Zuo S, Uemura R, Dai YS, Wang Y, Haider HK, Li T, Xu M: Mobilized bone marrow progenitor cells serve as donors of cytoprotective genes for cardiac repair. J Mol Cell Cardiol 44:607-617, 2008.
85. Dai Y, Xu M, Wang Y, Pasha Z, Li T, Ashraf M: HIF-lalpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. J Mol Cell Cardiol 42:1036-1044, 2007.
86. Xu M, Uemura R, Dai Y, Wang Y, Pasha Z, Ashraf M: In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol 42:441-148, 2007.
87. Cain BS, Meldrum DR, Meng X, Dinarello CA, Shames BD, Banerjee A, Harken AH: p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. J Surg Res 83:7-12, 1999.
88. MeldrumDR, Dinarello CA, Cleveland JC Jr, Cain BS, Shames BD, Meng X, Harken AH: Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery 124:291-296; discussion 297, 1998.
89. Chen CH, Liu K, Chan JY: Anesthetic preconditioning confers acute cardioprotection via up-regulation of manganese superoxide dismutase and preservation of mitochondrial respiratory enzyme activity. Shock 29: 300-308, 2008.
90. Wairiuko GM, Crisostomo PR, Wang M, Morrell ED, Meldrum KK, Lillemoe KD, Meldrum DR: Stem cells improve right ventricular functional recovery after acute pressure overload and ischemia reperfusion injury. J Surg Res 141:241-246, 2007.
91. Wang M, Tsai BM, Crisostomo PR, Meldrum DR: Pretreatment with adult progenitor cells improves recovery and decreases native myocardial proinflammatory signaling after ischemia. Shock 25:454-459, 2006.
92. Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, Koskinen PK, Lemstrom KB: Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107:1308-1314, 2003.
93. Shim WS, Li W, Zhang L, Li S, Ong HC, Song IC, Bapna A, Ge R, Lim YT, Chuah SC, et al.: Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model. J Biomed Sci 13:579-591, 2006.
94. Lijie S, Ming C, Zuoyan W, Xinheng F, Jieming M, Ping C, Kangtao M, Fengrong C, Chunyan Z: Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction. Biochem Biophys Res Co 357:779-784, 2007.
95. Sandhu R, Teichert-Kuliszewska K, Nag S, Proteau G, Robb MJ, Campbell AI, Kuliszewski MA, Kutryk MJ, Stewart DJ: Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat. Cardiovasc Res 64:115-124, 2004.
96. Gao F, He T, Wang H, Yu S, Yi D, Liu W, Cai Z: A promising strategy for the treatment of ischemic heart disease: mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol 23: 891-898, 2007.
97. Boodhwani M, Sodha NR, Laham RJ, Sellke FW: The future of therapeutic myocardial angiogenesis. Shock 26:332-341, 2006.
98. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106:3009-3017, 2002.
99. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, et al.: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364:141-148, 2004.
100. Erbs S, Linke A, Schachinger V, Assmus B, Thiele H, Diederich KW, Hoffmann C, Dimmeler S, Tonn T, Hambrecht R, et al.: Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation 116:366-374, 2007.
101. Shapiro NI, Yano K, Okada H, Fischer C, Howell M, Spokes KC, Ngo L, Angus DC, Aird WC: A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock 29:452-457, 2008.
102. Henrich D, Hahn P, Wahl M, Wilhelm K, Dernbach E, Dimmeler S, Marzi I: Serum derived from multiple trauma patients promotes the differentiation of endothelial progenitor cells in vitro: possible role of transforming growth factor-betal and vascular endothelial growth factorl65. Shock 21:13-16, 2004.
103. Mofarrahi M, Nouh T, Qureshi S, Guillot L, Mayaki D, Hussain SN: Regulation of angiopoietin expression by bacterial lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 294:L955-L963, 2008.
104. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 179: 1855-1863, 2007.
105. Huang YQ, Sauthoff H, Herscovici P, Pipiya T, Cheng J, Heitner S, Szentirmai O, Carter B, Hay JG: Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury. Crit Care Med 36:262-267, 2008.
106. McCarter SD, Mei SH, Lai PF, Zhang QW, Parker CH, Suen RS, Hood RD, Zhao YD, Deng Y, Han RN, Dumont DJ, et al.: Cell-based angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care Med 175: 1014-1026, 2007.
107. Xu J, Qu J, Cao L, Sai Y, Chen C, He L, Yu L: Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 214:472-481, 2008.
108. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ: Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 4:e269, 2007.
109. Buemi M, Galeano M, Sturiale A, Ientile R, Crisafulli C, Parisi A, Catania M, Calapai G, Impala P, Aloisi C, et al.: Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock 22: 169-173, 2004.
110. Haider H, Sim EK, Lei Y, Ashraf M: Cell-based ex vivo delivery of angiogenic growth factors for cardiac repair. Arterioscler Thromb Vasc Biol 25:el44, 2005.
111. Crisostomo PR, Wang M, Wairiuko GM, Morrell ED, Terrell AM, Seshadri P, Nam UH, Meldrum DR: High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock 26:575-580, 2006.
112. Ye L, Haider H, Jiang S, Tan RS, Toh WC, Ge R, Sim EK: Angiopoietin-1 for myocardial angiogenesis: a comparison between delivery strategies. Eur J Heart Fail 9:458-465, 2007.
113. Haider H, Ashraf M: Bone marrow cell transplantation in clinical perspective. J Mol Cell Cardiol 38:225-235, 2005.
114. Novotny NM, Ray R, Markel T, Crisostomo PR, Wang M, Wang Y, Meldrum DR: Stem cell therapy in myocardial repair and remodeling. J Am Coll Surg 207:423-434, 2008.
115. Wang T, Tang W, Sun S, Ristagno G, Huang Z, Weil MH: Intravenous infusion of bone marrow mesenchymal stem cells improves myocardial function in a rat model of myocardial ischemia. Crit Care Med 35: 2587-2593, 2007.
116. Templin C, Kotlarz D, Marquart F, Faulhaber J, Brendecke V, Schaefer A, Tsikas D, Bonda T, Hilfiker-Kleiner D, Ohl L, et al.: Transcoronary delivery of bone marrow cells to the infarcted murine myocardium: feasibility, cellular kinetics, and improvement in cardiac function. Basic Res Cardiol 101: 301-310, 2006.
117. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis M, Wilensky RL: A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 27: 1114-1122,2006.
118. Perm EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, et al.: Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107:2294-2302, 2003.